An Abrysvo-Shaped Hole: CDC Panel’s Beyfortus Vote Couldn’t Consider Pfizer’s Pending Vaccine

 
• By Bridget Silverman

The prospect of a game-changing approval of Pfizer’s maternal RSV vaccine hung over CDC committee’s vote on AstraZeneca/Sanofi’s Beyfortus, even though the pending product could not be addressed.

RSV watercolor
• Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers